Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

A WOMAN who has lost 6st using weight loss jabs has warned against one of the hidden side effects. Kelly Kay, from the UK, took to social media showing off her weight loss transformation, and ...

Patients should be monitored for a year after stopping weight loss jabs to prevent them piling the pounds back on, new ...

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to ...

Shares of Hims and Hers Health (NYSE:HIMS) slid 14% in premarket trading following the telehealth company’s announcement of ...

The National Institute for Health and Care Excellence (Nice) issues advice as 1.5 million Brits are using weight loss ...

The company has big ambitions. It wants to reach at least $6.5 billion in sales by 2030. In the short term, as it tries to steer its consumers to high-end daily products, Chief Financial Officer Yemi ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Consensus analyst estimates for Novo Nordisk (NVO) earnings per share and revenue land at $0.92 and $11.9 billion, ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Noom introduces affordable options for obesity treatments, including Novo Nordisk's Wegovy and GLP-1Rx programs. Read more ...